Core Viewpoint - Zenas BioPharma, a clinical-stage biopharmaceutical company, has announced the pricing of a $200 million public offering of convertible senior notes and a $100 million equity offering, aiming to raise approximately $287.5 million in net proceeds to support its product development and commercialization efforts [1][2]. Group 1: Offerings Details - The company is offering $200 million in 2.50% convertible senior notes due 2032 and 5 million shares of common stock at $20.00 per share [1]. - The net proceeds from both offerings are estimated to be around $287.5 million after deducting underwriting discounts and expenses [2]. - The offerings are expected to close on March 31, 2026, subject to customary closing conditions [3]. Group 2: Convertible Notes Characteristics - The convertible notes will be unsecured senior obligations, accruing interest at 2.50% per year, with a maturity date of April 1, 2032 [4]. - Noteholders can convert their notes under certain conditions, with an initial conversion rate of 37.7358 shares per $1,000 principal amount, equating to a conversion price of approximately $26.50 per share [5]. - The notes are redeemable at the company's option after April 8, 2030, under specific conditions related to the stock price [6]. Group 3: Use of Proceeds - The company intends to use the proceeds to support the U.S. commercial launch of obexelimab for IgG4-RD treatment, advance its development pipeline, and for general corporate purposes [8]. Group 4: Company Overview - Zenas BioPharma focuses on developing transformative therapies for autoimmune diseases, with key products including obexelimab and orelabrutinib [13]. - Obexelimab is designed to inhibit pathogenic B cells without depleting them, while orelabrutinib targets B cells in both peripheral and central nervous systems [13].

Core Viewpoint - Zenas BioPharma, a clinical-stage biopharmaceutical company, has initiated underwritten public offerings for convertible senior notes due 2032 and shares of its common stock to support its commercial launch and development pipeline for autoimmune disease therapies [1][5]. Offering Details - The company is offering convertible senior notes with a maturity date of April 1, 2032, and will pay interest semi-annually [4]. - Underwriters will have a 30-day option to purchase an additional 15% of the convertible notes and shares of common stock to cover over-allotments [2]. Use of Proceeds - The net proceeds from the offerings are intended to support the U.S. commercial launch of obexelimab for IgG4-RD treatment, advance the development pipeline, and cover working capital and general corporate purposes [5]. Company Overview - Zenas BioPharma focuses on developing transformative therapies for autoimmune diseases, with lead candidates including obexelimab and orelabrutinib [10]. - Obexelimab is designed to inhibit pathogenic B cells without depleting them, while orelabrutinib targets B cells in both peripheral and central nervous systems [10].

Core Insights - Zenas BioPharma is preparing to submit marketing applications for obexelimab for IgG4-RD to the FDA in Q2 2026 and to the EMA in H2 2026, following positive Phase 3 INDIGO trial results [1][4] - The company anticipates topline results from the Phase 2 SunStone trial for systemic lupus erythematosus (SLE) in Q4 2026 [1][4] - Zenas has secured up to $250 million in non-dilutive debt financing from Pharmakon, enhancing its financial flexibility for commercialization and pipeline investments [1][6] Corporate Highlights - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, showing a 56% reduction in IgG4-RD flare risk compared to placebo in the INDIGO trial [4][12] - The company is advancing multiple pipeline programs, including orelabrutinib for multiple sclerosis (MS) and ZB021, an oral IL-17AA/AF inhibitor, with Phase 1 trials expected to start in Q2 2026 [2][3][7] - ZB014, a new half-life extended anti-CD-19 and FcγRIIb antibody, is also progressing toward clinical development [3][4] Financial Results - For the year ended December 31, 2025, Zenas reported revenue of $10 million, primarily from a license agreement, compared to $5 million in 2024 [10][11] - Research and development expenses increased to $168.1 million in 2025 from $139.1 million in 2024, driven by higher personnel and clinical trial costs [13][21] - The net loss for the year was $377.7 million, compared to a net loss of $157.0 million in 2024 [13][21] Balance Sheet - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $360.5 million, up from $350.8 million in 2024 [22] - Total liabilities increased to $141.5 million from $57.5 million in 2024, reflecting the new debt facility [22] - The accumulated deficit reached $765.1 million as of December 31, 2025, compared to $387.4 million in 2024 [22]

Core Insights - Obexelimab demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial, indicating significant efficacy in treating Relapsing Multiple Sclerosis (RMS) [1][2] - The 24-week data further confirmed the drug's robust and durable activity, maintaining significant reductions in lesions and improving biomarkers associated with disease activity [3][4] - The safety profile of obexelimab was consistent with previous trials, showing good tolerability without new safety signals [2][3] Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [12] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting B cell activity [12] - Zenas plans to submit a Biologics License Application (BLA) for obexelimab in the second quarter of 2026 and a Marketing Authorization Application (MAA) in the second half of 2026 for Immunoglobulin G4-Related Disease [11][12] Clinical Trial Details - The Phase 2 MoonStone trial enrolled 116 patients and was designed to evaluate the efficacy and safety of obexelimab in RMS, using MRI endpoints to measure treatment outcomes [9] - The trial's primary endpoint was the cumulative number of new gad-enhancing T1 lesions over weeks 8 and 12, with secondary endpoints assessing disease progression through various biomarkers [9] - Following the double-blind phase, patients transitioned to an open-label period to continue treatment and assess long-term outcomes [9] Mechanism of Action - Obexelimab is a bifunctional monoclonal antibody that binds to CD19 and FcγRIIb, inhibiting B cell activity without depleting them, which is crucial for addressing autoimmune diseases [10][12] - The drug's unique mechanism and self-administered subcutaneous injection regimen may effectively target the pathogenic role of B cells in chronic autoimmune conditions [10][12]

Core Insights - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [3] - The company will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 [1] Company Overview - Zenas aims to lead in the development and commercialization of therapies for autoimmune diseases, leveraging an experienced leadership team and a disciplined product candidate acquisition strategy [3] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib [3] - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, designed to inhibit pathogenic B cells without depleting them [3] - Orelabrutinib is a selective CNS-penetrant oral small molecule BTK inhibitor that targets pathogenic B cells in both peripheral and central nervous systems [3] - Zenas also has earlier stage programs, including ZB021, an oral IL-17AA/AF inhibitor, and ZB022, a brain-penetrant TYK2 inhibitor [3]

Core Insights - Zenas BioPharma's phase III INDIGO study for obexelimab in treating IgG4-related disease has met its primary endpoint, showing a significant reduction in flare risk [1][2][7] Study Results - Obexelimab demonstrated a 56% reduction in the risk of IgG4-RD flare compared to placebo over a 52-week period, achieving the primary endpoint of the INDIGO study [2][7] - The treatment also showed significant efficacy across four key secondary endpoints, including reductions in investigator-assessed flares and the number of flares requiring rescue therapy [3][7] Market Reaction - Despite the positive study results, Zenas BioPharma's shares fell by 51.9% on January 5, indicating that the efficacy data may not have met investor expectations [4][7] Future Plans - The company plans to submit a biologics license application to the FDA for obexelimab in Q2 2026 and a marketing authorization application to the European Medicines Agency in the second half of 2026 [5][7] Ongoing Development - Zenas BioPharma is also exploring obexelimab for other autoimmune diseases, with ongoing studies for systemic lupus erythematosus and multiple sclerosis [8][9] - The company is focused on the successful development of obexelimab and other pipeline candidates, as it currently lacks a marketed product [10] Stock Performance - Over the past six months, Zenas BioPharma's shares have increased by 69.7%, outperforming the industry average rise of 21.5% [6]

Summary of Zenas BioPharma Conference Call Company Overview - **Company**: Zenas BioPharma (NasdaqGS: ZBIO) - **Focus**: Development of obexelimab for the treatment of immunoglobulin G4-related disease (IgG4-RD) Key Industry Insights - **Disease Prevalence**: Estimated diagnosed prevalence of IgG4-RD in the U.S. is around 20,000 patients, with total prevalence (including undiagnosed) potentially reaching 40,000. Similar global prevalence is suggested [doc id='9'] - **Market Opportunity**: The market opportunity for IgG4-RD treatment is approximately $3 billion in the U.S. and $2 billion in Europe, with over half of diagnosed patients experiencing frequent flares [doc id='17'] Core Findings from INDIGO Trial - **Trial Results**: The INDIGO trial met its primary endpoint, showing a 56% reduction in the risk of IgG4-RD flare compared to placebo, with a hazard ratio of 0.443 and a p-value of 0.0005 [doc id='12'] - **Secondary Endpoints**: All four key secondary endpoints were met, including time to first flare and the proportion of patients achieving complete remission [doc id='13'] - **Safety Profile**: Obexelimab demonstrated a compelling safety and tolerability profile, with lower incidences of serious adverse events and infections compared to placebo [doc id='15] Treatment Advantages - **Mechanism of Action**: Obexelimab's unique inhibitory mechanism targets B-cells without depleting them, which may provide advantages over existing therapies like Uplizna [doc id='16'] - **Administration**: The drug is administered subcutaneously at home, aligning with patient preferences and reducing the need for infusion center visits [doc id='16'] - **Cost-Effectiveness**: The at-home administration model may lead to lower out-of-pocket costs for patients compared to high-priced infused therapies [doc id='17'] Future Plans - **Regulatory Submissions**: Plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q2 and a marketing authorization application to the European Medicines Agency in the second half of the year [doc id='6'] - **Pipeline Expansion**: Zenas is advancing multiple candidates, including orelabrutinib and ZBO21, into clinical trials, aiming to establish a strong portfolio in autoimmune diseases [doc id='19'] Market Dynamics - **Underdiagnosis**: IgG4-RD is currently underdiagnosed, and the approval of obexelimab could enhance disease recognition and treatment [doc id='18'] - **Competitive Landscape**: The efficacy and safety profile of obexelimab positions it as a potential first-line therapy, especially for older patients who may not tolerate B-cell depletion [doc id='24'] Additional Insights - **KOL Feedback**: Key opinion leaders expressed enthusiasm for obexelimab's efficacy and safety, viewing it as a strong candidate for first-line treatment [doc id='23'] - **Payer Discussions**: Preliminary conversations with payers indicate a favorable view of obexelimab's risk-benefit profile, especially in comparison to existing therapies [doc id='49'] Conclusion - **Transformational Year**: 2025 was highlighted as a transformational year for Zenas, with the INDIGO results expected to drive momentum into 2026 and beyond [doc id='18']

Core Insights - Zenas BioPharma announced positive results from the Phase 3 INDIGO trial of obexelimab, showing a 56% reduction in the risk of IgG4-RD flare compared to placebo, with a Hazard Ratio of 0.44 and p=0.0005 [1][2] - Obexelimab demonstrated statistically significant activity on all four key secondary efficacy endpoints, including reduction in flares requiring rescue therapy and the proportion of patients achieving complete remission [1][2] - The company plans to submit a Biologics License Application (BLA) to the FDA in Q2 2026 and a Marketing Authorization Application (MAA) to the EMA in H2 2026 [1][2] Company Overview - Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune diseases [15] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting IgG4-RD [15] - Zenas aims to address the unmet medical needs of patients with autoimmune diseases through innovative therapies [15] Clinical Trial Details - The Phase 3 INDIGO trial enrolled 194 patients and was designed to evaluate the safety and efficacy of obexelimab over a 52-week period [10] - The primary endpoint was the time to first IgG4-RD flare requiring rescue therapy, with key secondary endpoints including the number of flares and the cumulative use of rescue therapy [11][12] - Obexelimab was well tolerated, with lower rates of infections and similar incidence of injection site reactions compared to placebo [1][2] Future Developments - Zenas expects to report topline results from the Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) in Q4 2026 [4] - The company is also studying orelabrutinib in a global Phase 3 trial for Primary Progressive Multiple Sclerosis (PPMS) and plans to initiate a trial for non-active Secondary Progressive Multiple Sclerosis (naSPMS) in Q1 2026 [4] - Zenas is preparing to initiate Phase 1 clinical development for two additional product candidates, ZB021 and ZB022, in 2026 [4]

Core Insights - InnoCare Pharma presented over 20 studies on its BTK inhibitor orelabrutinib at the 67th Annual Meeting of the American Society of Hematology (ASH) [1] Efficacy and Safety - Orelabrutinib has shown significant efficacy and safety across multiple lymphoma types, including marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), primary central nervous system lymphoma (PCNSL), and diffuse large B-cell lymphoma (DLBCL) [2] - In a study involving newly diagnosed PCNSL, the combination of orelabrutinib, rituximab, and high-dose methotrexate achieved an objective response rate (ORR) of 89.5% and a complete response (CR) rate of 78.9% [4] - The orelabrutinib and obinutuzumab combination demonstrated an ORR of 96.0% in treatment-naïve MZL patients, with no severe toxicities reported [6][5] - Orelabrutinib combined with rituximab showed an ORR of 81.8% and a CR rate of 72.7% in treatment-naïve MZL patients who were unsuitable for local therapy [7][8] - The orelabrutinib plus bendamustine-rituximab regimen showed promising tumor response and survival outcomes in transplant-ineligible, intermediate- to high-risk MCL patients [9] Real-World Studies - A large-scale real-world study in China indicated that R-CHOP plus orelabrutinib achieved a CR rate of 81.4% in MCD-like DLBCL patients, supporting subtype-directed therapy [11] - Preliminary results from a phase II study suggest that the PRO-Pola regimen is a potential treatment option for elderly, unfit, or frail DLBCL patients, with a CRR of 77.8% and an ORR of 100% among those completing three cycles [12][13] - A retrospective real-world study indicated that orelabrutinib monotherapy achieved an ORR and disease control rate (DCR) of 100% in CLL patients [14] Future Directions - Additional studies on orelabrutinib have been selected for poster presentation and publication at the 2025 ASH Annual Meeting, indicating ongoing research and development efforts [15]

Core Viewpoint - InnoCare Pharma has presented over 20 studies on its BTK inhibitor orelabrutinib at the 67th Annual Meeting of the American Society of Hematology, highlighting its efficacy and safety in treating various lymphomas and chronic lymphocytic leukemia [1][2]. Group 1: Efficacy and Safety of Orelabrutinib - Orelabrutinib has shown significant efficacy in multiple lymphoma types, including marginal zone lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, primary central nervous system lymphoma, and diffuse large B-cell lymphoma [2]. - In a study involving newly diagnosed primary central nervous system lymphoma, the combination of orelabrutinib, rituximab, and high-dose methotrexate achieved an objective response rate (ORR) of 89.5% and a complete response (CR) rate of 78.9% [4]. - The orelabrutinib and obinutuzumab combination demonstrated an ORR of 96.0% in treatment-naïve marginal zone lymphoma patients, with no severe toxicities reported [5][6]. Group 2: Treatment Outcomes and Comparisons - The orelabrutinib plus bendamustine-rituximab regimen showed promising tumor response and survival outcomes compared to the standard bendamustine-rituximab regimen in transplant-ineligible, intermediate- to high-risk mantle cell lymphoma [9]. - In a large-scale real-world study of diffuse large B-cell lymphoma in China, the R-CHOP regimen combined with orelabrutinib achieved a CR rate of 81.4% in MCD-like patients, supporting subtype-directed therapy [11]. - A prospective phase II study indicated that the combination of pomalidomide, rituximab, and orelabrutinib is a potential treatment option for elderly, unfit, or frail patients with diffuse large B-cell lymphoma, achieving a CR rate of 77.8% among those who completed three cycles [12][13][14]. Group 3: Future Research and Development - Additional studies on orelabrutinib have been selected for poster presentation and publication at the 2025 ASH Annual Meeting, indicating ongoing research and development efforts [15]. - InnoCare is committed to discovering and commercializing innovative drugs for cancer and autoimmune diseases, with a focus on addressing unmet medical needs [17].